The earliest neutralizing antibodies (NAbs) following infection are specific for the transmitted founder (TF) virus and often select for escape mutations that alter the TF glycan shield (Bar et al., 2012; Bonsignori et al., 2017; Frost et al., 2005; Moore et al., 2009; Richman et al., 2003; Wei et al., 2003). Here, TF is linked to infection.